{"id":9796,"date":"2020-12-28T11:58:37","date_gmt":"2020-12-28T11:58:37","guid":{"rendered":"http:\/\/www.16news.com.au\/?p=9796"},"modified":"2020-12-28T11:58:37","modified_gmt":"2020-12-28T11:58:37","slug":"pbs-listings-bring-greater-hope-in-fight-against-multiple-myeloma-and-severe-psoriasis","status":"publish","type":"post","link":"http:\/\/www.16news.com.au\/index.php\/2020\/12\/28\/pbs-listings-bring-greater-hope-in-fight-against-multiple-myeloma-and-severe-psoriasis\/","title":{"rendered":"PBS listings bring greater hope in fight against multiple myeloma and severe psoriasis"},"content":{"rendered":"

The first day of the new year will bring with it new hope for Australians fighting one of the most common blood cancers, thanks to a critical new medicines listing on the Pharmaceutical Benefits Scheme (PBS).
\nFrom 1 January 2021, Darzalex\u00ae<\/sup>\u00a0(daratumumab) will be listed for the first time in combination with bortezomib and dexamethasone, as a second-line treatment for patients with multiple myeloma \u2013 a cancer of the plasma cells.
\nAround 1,165 patients will benefit from access to this treatment, which might otherwise cost up to $160,000 a year. Patients could now pay as little as $41.30 per script, or $6.60 with a concession card.
\nDarzalex\u00ae<\/sup>\u00a0mobilises the patient\u2019s own immune system to fight the disease.
\nThis treatment will bring improved clinical outcomes and quality of life for those affected by this disease.
\nIn 2020, it is estimated more than 2,300 new cases of multiple myeloma will be diagnosed in Australia.
\nAbout 18,000 people in Australia are living with this serious condition at any one time.
\nAlso from 1 January 2021, Australians living with severe chronic psoriasis will benefit from the first time listing of Otezla\u00ae<\/sup>\u00a0(apremilast) on the PBS.
\nAround 5,000 patients with severe chronic psoriasis might pay more than $7,500 a year for treatment without this listing.
\nAround 1.6 million Australians live with some form of psoriasis\u2014a long-term inflammatory skin condition. People who suffer with the most severe and chronic forms of the disease also have an increased risk of developing diabetes and cardiovascular disease.
\nThe source of inflammation in psoriasis is thought to be caused by an enzyme, PDE4. Otezla\u00ae<\/sup>\u00a0works to reduce the PDE4 activity and the subsequent inflammation.
\nBoth Tagrisso\u00ae<\/sup>\u00a0and Otezla\u00ae<\/sup>\u00a0have been recommended by the independent Pharmaceutical Benefits Advisory Committee (PBAC).
\nSince 2013, the Australian Government has approved over 2,500 new or amended listings on the PBS.
\nThis represents an average of around 30 listings or amendments per month \u2013 or one each day \u2013 at an overall investment by the Government of close to $12 billion.
\nChanges to PBS co\u2011payment and safety net thresholds come into effect on 1 January each year. The changes are calculated in accordance with the\u00a0National Health Act 1953<\/i>\u00a0and are indexed based on the Consumer Price Index.
\nThe PBS co\u2011payment for concession card\u2011holders will remain capped at $6.60 per script in 2021. The safety net threshold for concession card\u2011holders will also remain at $316.80 per year. When a concession card-holder reaches the Safety Net threshold, they will be eligible for a Safety Net Card and receive PBS medicines free of charge for the rest of 2021.
\nThe maximum co\u2011payment for general patients will be $41.30 per PBS script in 2021.
\nThe Government\u2019s commitment to ensuring that Australians can access affordable medicines, when they need them, remains rock solid.<\/p>\n","protected":false},"excerpt":{"rendered":"

The first day of the new year will bring with it new hope for Australians fighting one of the most common blood cancers, thanks to a critical new medicines listing on the Pharmaceutical Benefits Scheme (PBS). From 1 January 2021, Darzalex\u00ae\u00a0(daratumumab) will be listed for the first time in combination with bortezomib and dexamethasone, as … Continue reading “PBS listings bring greater hope in fight against multiple myeloma and severe psoriasis”<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-9796","post","type-post","status-publish","format-standard","hentry","category-aussie"],"_links":{"self":[{"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/posts\/9796","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=9796"}],"version-history":[{"count":0,"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/posts\/9796\/revisions"}],"wp:attachment":[{"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=9796"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=9796"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=9796"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}